The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
MD · Healthcare · No moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | MD | QURE | CNMD | ISCO |
|---|---|---|---|---|
| Moat Score (0–100) | 39 (highest) | 39 (highest) | 39 (highest) | 39 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 57 (highest) | 15 | 56 | 52 |
| Pricing power | — | 96 (highest) | 92 | 92 |
| Returns on capital | 8 (highest) | 7 | 0 | 0 |
| Balance-sheet safety | 51 | 55 (highest) | 3 | 28 |
| Capital allocation | 40 | 24 | 45 (highest) | 24 |
| 216% above value if growth stopped today | No price data | 36% above value if growth stopped today (largest discount to value if growth stopped today) | No price data | |
| Market cap | $2.3B | $1.4B | $1.5B | $2.1M |
| Moat tier | No moat | No moat | No moat | No moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |